LYTIX BIOPHARMA ASA: årsregnskap 2025 vs 2024
Shrank 100% on revenue, stronger earnings, cash halved-plus
approved 2026-04-14; registry 2026-08-06; journal 2026 688329
Summary
What changed
Comparing Årsregnskap 2025 with 2024 for LYTIX BIOPHARMA ASA. Revenue 11.13m NOK → 11.1k NOK (-99.9%). Net result -94.27m NOK → -59.98m NOK. Equity 107.89m NOK → 61.75m NOK.
On the constructive side: operating result improved; net result improved. Pressures included: revenue fell; equity eroded; cash fell.
Also worth watching: sharp cash drawdown; paid-in equity reduced; book investments changed. All figures are taken from the published annual accounts for LYTIX BIOPHARMA ASA.
At a glance
Scorecard
What improved
-
↑
Operating result improved
Operating result -95.90m NOK → -64.03m NOK (op. margin -861.3% → -575067.4%). Calculated
-
↑
Net result improved
Net result -94.27m NOK → -59.98m NOK (net margin -846.6% → -538728.2%). Calculated
What deteriorated
-
↓
Revenue fell
Operating income / revenue moved from 11.13m NOK to 11.1k NOK (-99.9% YoY). Calculated
-
↓
Equity eroded
Book equity 107.89m NOK → 61.75m NOK (equity ratio 73.6% → 75.7%). Calculated
-
↓
Cash fell
Bank deposits 130.79m NOK → 10.60m NOK (-91.9% YoY). Calculated
Things to notice
-
·
Sharp cash drawdown
Cash fell by more than 60% YoY (130.79m NOK → 10.60m NOK). Check whether funds moved to group receivables, investments, or operating burn. Interpretation
-
·
Paid-in equity reduced
Paid-in equity fell 107.89m NOK → 61.75m NOK — check capital reduction, conversion, or reclassification. Interpretation
-
·
Book investments changed
Investment / intangible book value 589 NOK → 2.08m NOK. Reported fact